The structure-function relationship of activated protein C

Summary

Protein C is the central enzyme of the natural anticoagulant pathway and its activated form APC (activated protein C) is able to proteolyse non-active as well as active coagulation factors V and VIII. Proteolysis renders these cofactors inactive, resulting in an attenuation of thrombin formation and overall down-regulation of coagulation. Presences of the APC cofactor, protein S, thrombomodulin, endothelial protein C receptor and a phospholipid surface are important for the expression of anticoagulant APC activity. Notably, APC also has direct cytoprotective effects on cells: APC is able to protect the endothelial barrier function and expresses anti-inflammatory and anti-apoptotic activities. Exact molecular mechanisms have thus far not been completely described but it has been shown that both the protease activated receptor 1 and EPCR are essential for the cytoprotective activity of APC. Recently it was shown that also other receptors like sphingosine 1 phosphate receptor 1, Cd11b/CD18 and tyrosine kinase with immunoglobulin-like and EGFlike domains 2 are likewise important for APC signalling. Mutagenesis studies are being performed to map the various APC functions and interactions onto its 3D structure and to dissect anticoagulant and cytoprotective properties. The results of these studies have provided a wealth of structure-function information. With this review we describe the state-of-the-art of the intricate structure-function relationships of APC, a protein that harbours several important functions for the maintenance of both humoral and tissue homeostasis.

Lessons from natural and engineered mutations

Keywords

Activated protein C - anticoagulation - cytoprotection - mutagenesis - structure-function

• References

• 1 Griffin JH, Fernandez JA, Gale AJ. et al. Activated protein C. J Thromb Haemost 2007; 5: 73-80.
• 2 Stearns-Kurosawa D, Kurosawa S, Mollica J. et al. The endothelial cell protein C receptor augments protein C activation by the thrombin-thrombomodulin complex. PNAS 1996; 96: 10212-10216.
• 3 Mather T, Oganessyan V, Hof P. et al. The 2.8 Å crystal structure of Gla-domainless activated protein C. EMBO J 1996; 15: 6822-6831.
• 4 UniProtKB/Swiss-Prot, PROC_HUMAN, accession number P04070. 2011
• 5 Grinnell B, Walls J, Gerlitz B. Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. J Biol Chem 1991; 266: 9778-9785.
• 6 Scully M, Toh C, Hoogendoorn H. et al. Activation of protein C and its distribution between its inhibitors, protein C inhibitor, alpha-1-antitrypsin and alpha-2-macroglobulin in patients with disseminated intravascular coagulation. Thromb Haemost 1993; 69: 448-453.
• 7 Heeb M, Gruber A, Griffin J. Identification of divalent metal ion-dependent inhibition of activated protein C by alpha-2-macroglobulin and alpha-2-antiplasmin in blood and comparisons to inhibition of factor Xa, thrombin and plasmin. J Biol Chem 1991; 266: 17606-17612.
• 8 Zhu T, Ubhayasekera W, Nickolaus N. et al. Zinc ions bind to and inhibit activated protein C. Thromb Haemost 2010; 104: 544-553.
• 9 Mammen EF, Thomas WR, Seegers WH. Activation of purified prothrombin to autoprothrombin I or autoprothrombin II (platelet cofactor II or autoprothrombin II-A). Throm Diath Haemorrh 1976; 5: 218-249.
• 10 Stenflo J. A new vitamin K-dependent protein. J Biol Chem 1976; 251: 355-363.
• 11 Kalafatis M, Rand M, Mann K. The mechanism of inactivation of human factor V and human factor Va by activated protein C. J Biol Chem 1994; 269: 31869-31880.
• 12 Nicolaes G, Tans G, Thomassen M. et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 21158-21166.
• 13 Rosing J, Hoekema L, Nicolaes G. et al. Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270: 27852-27858.
• 14 Yegneswaran S, Wood G, Esmon C. et al. Protein S alters the active site location of activated protein C above the membrane surface. A fluorescence resonance energy transfer study. J Biol Chem 1997; 272: 25013-25021.
• 15 Yegneswaran S, Smirnov M, Safa O. et al. Relocating the active site of activated protein C eliminates the need for its protein S cofactor. A fluorescence resonance energy transfer study. J Biol Chem 1999; 274: 5462-5468.
• 16 Segers K, Dahlbäck B, Rosing J. et al. Identification of surface epitopes of human coagulation factor Va that are important for interaction with activated protein C and heparin. J Biol Chem 2008; 283: 22573-22581.
• 17 Nicolaes GAF, Bock PE, Segers K. et al. Inhibition of thrombin formation by active site mutated (S360A) activated protein C. J Biol Chem 2010; 285: 22890-22900.
• 18 Kim P, Nesheim M. Down regulation of prothrombinase by activated protein C during prothrombin activation. Thromb Haemost 2010; 104: 61-70.
• 19 Fay P, Smudzin T, Walker F. Activated protein C-catalyzed inactivation of human factor VIII and factor VIIIa. Identification of cleavage sites and correlation of proteolysis with cofactor activity. J Biol Chem 1991; 266: 20139-20145.
• 20 Amano K, Michnick D, Moussalli M. et al. Mutation at either Arg336 or Arg562 in factor VIII is insufficient for complete resistance to activated protein C (APC)-mediated inactivation: implications for the APC resistance test. Thromb Haemost 1998; 79: 557-563.
• 21 Nyberg P, Dahlbäck B, Garcia de Frutos P. The SHBG-like region of protein S is crucial for factor V-dependent APC-cofactor function. FEBS Lett 1998; 433: 28-32.
• 22 Thorelli E, Kaufman RJ, Dahlbäck B. Cleavage of factor V at Arg 506 by activated protein C and the expression of anticoagulant activity of factor V. Blood 1999; 93: 2552-2558.
• 23 Thorelli E, Kaufman R, Dahlbäck B. The C-terminal region of the factor V B-domain is crucial for the anticoagulant activity of factor V. J Biol Chem 1998; 273: 16140-16145.
• 24 Lollar P, Parker C. pH-dependent denaturation of thrombin-activated porcine factor VIII. J Biol Chem 1990; 265: 1688-1692.
• 25 Nicolaes G, Dahlbäck B. Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states. Hematol Oncol Clin North Am 2003; 17: 37-61.
• 26 Nicolaes GAF, Dahlbäck B. Congenital and acquired activated protein C resistance. Semin Vasc Med 2003; 3: 33-46.
• 27 Dahlbäck B, Villoutreix BO. Regulation of blood coagulation by the protein C anticoagulant pathway. Novel insights into structure-function relationships and molecular recognition. Vasc Biol 2005; 25: 1311-1320.
• 28 Broekmans AW, Veltkamp JJ, Bertina RM. Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. N Engl J Med 1983; 309: 340-344.
• 29 Griffin JH, Evatt B, Zimmerman TS. et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370-1373.
• 30 Zorio E, Navarro S, Medina P. et al. Circulating activated protein C is reduced in young survivors of myocardial infarction and inversely correlates with the severity of coronary lesions. J Thromb Haemost 2006; 4: 1530-1536.
• 31 España F, Vayá A, Mira Y. et al. Low level of circulating activated protein C is a risk factor for venous thromboembolism. Thromb Haemost 2001; 86: 1368-1373.
• 32 Marlar R, Neumann A. Neonatal purpura fulminans due to homozygous protein C or protein S deficiencies. Semin Thromb Hemost 1990; 16: 299-309.
• 33 Marlar RA, Montgomery RR, Broekmans AW. Diagnosis and treatment of homozygous protein C deficiency. Report of the Working Party on Homozygous Protein C Deficiency of the Subcommittee on Protein C and Protein S, International Committee on Thrombosis and Haemostasis. J Pediatr 1989; 114: 528-534.
• 34 Seligsohn U, Berger A, Abend M. et al. Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med 1984; 310: 559-562.
• 35 Branson HE, Katz J, Marble R. et al. Inherited protein C deficiency in a neonate. Lancet 1983; 2: 1165-1168.
• 36 Jackson C, Xue M, Thompson P. et al. Activated protein C prevents inflammation yet stimulates angiogenesis to promote cutaneous wound healing. Wound Repair Regen 2005; 13: 284-294.
• 37 Isobe H, Okajima K, Uchiba M. et al. Activated protein C prevents endotoxin-induced hypotension in rats by inhibiting excessive production of nitric oxide. Circulation 2001; 104: 1171-1175.
• 38 Taylor Fj, Chang A, Esmon C. et al. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987; 79: 918-925.
• 39 Iba T, Kidokoro A, Fukunaga M. et al. Activated protein C improves the visceral microcirculation by attenuating the leukocyte-endothelial interaction in a rat lipopolysaccharide model. Crit Care Med 2005; 33: 368-372.
• 40 Xue M, Thompson P, Sambrook P. et al. Activated protein C stimulates expression of angiogenic factors in human skin cells, angiogenesis in the chick embryo and cutaneous wound healing in rodents. Clin Hemorheol Microcirc 2006; 34: 153-161.
• 41 Zlokovic B, Zhang C, Liu D. et al. Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol 2005; 58: 474-477.
• 42 Liu D, Cheng T, Guo H. et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004; 10: 1479-1483.
• 43 Cheng T, Petraglia A, Li Z. et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med 2006; 12: 1278-1285.
• 44 Murakami K, Okajima K, Uchiba M. et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996; 87: 642-647.
• 45 Abraham E, Reinhart K, Opal S. et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial. J Am Med Assoc 2003; 290: 238-247.
• 46 Warren BL, Eid A, Singer P. et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. J Am Med Assoc 2001; 286: 1869-1878.
• 47 Bernard GR, Vincent JL, Laterre PF. et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
• 48 Martí-Carvajal A, Solà I, Lathyris D. et al. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2011; CD004388
• 49 Coughlin S. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
• 50 Ossovskaya VS, Bunnet NW. Protease-activated receptors: contribution to physiology and disease. Physiol Rev 2004; 84: 579-621.
• 51 Nakamura M, Gabazza E, Imoto I. et al. Anti-inflammatory effect of activated protein C in gastric epithelial cells. J Thromb Haemost 2005; 3: 2721-2729.
• 52 Bae J, Yang L, Rezaie A. Receptors of the protein C activation and activated protein C signaling pathways are colocalized in lipid rafts of endothelial cells. Proc Natl Acad Sci USA 2007; 104: 2867-2872.
• 53 Gorbacheva L, Davidova O, Sokolova E. et al. Endothelial protein C receptor is expressed in rat cortical and hippocampal neurons and is necessary for protective effect of activated protein C at glutamate excitotoxicity. J Neurochem 2009; 111: 967-975.
• 54 Gillibert-Duplantier J, Rullier A, Neaud V. et al. Liver myofibroblasts activate protein C and respond to activated protein C. World J Gastroenterol 2010; 16: 210-216.
• 55 Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172.
• 56 Loubele ST, Spek CA, Leenders P. et al. Activated protein C protects against myocardial ischemia/reperfusion injury via inhibition of apoptosis and inflammation. Arterioscler Thromb Vasc Biol 2009; 29: 1087-1092.
• 57 Fernandez JA, Xu X, Liu D. et al. Recombinant murine activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis 2003; 30: 271-276.
• 58 Yang X, Banerjee Y, Fernandez J. et al. Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. PNAS 2009; 106: 274-279.
• 59 Cao C, Gao Y, Li Y. et al. The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b. J Clin Invest 2010; 120: 1971-1980.
• 60 Xue M, Chow S, Dervish S. et al. Activated protein C enhances human keratinocyte barrier integrity via sequential activation of epidermal growth factor receptor and Tie2. J Biol Chem 2011; 286: 6742-6750.
• 61 Joyce DE, Gelbert L, Ciaccia A. et al. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001; 276: 11199-11203.
• 62 Kerschen E, Hernandez I, Zogg M. et al. Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest 2010; 120: 3167-3178.
• 63 Mosnier L, Griffin J. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003; 373: 65-70.
• 64 Cheng T, Dong L, Griffin J. et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9: 338-342.
• 65 Guo H, Liu D, Gelbard H. et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 2004; 41: 563-572.
• 66 Riewald M, Petrovan R, Donner A. et al. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-1882.
• 67 Gateau-Roesch O, Argaud L, Ovize M. Mitochondrial permeability transition pore and postconditioning. Cardiovasc Res 2006; 70: 264-273.
• 68 Rodrigues S, Granger D. Role of blood cells in ischaemia-reperfusion induced endothelial barrier failure. Cardiovasc Res 2010; 87: 291-299.
• 69 Minhas N, Xue M, Fukudome K. et al. Activated protein C utilizes the angiopoietin/Tie2 axis to promote endothelial barrier function. FASEB J 2009; 24: 873-881.
• 70 Bae JS, Yang L, Manithody C. et al. Engineering a disulfide bond to stabilize the calcium-binding loop of activated protein C eliminates its anticoagulant but not its protective signaling properties. J Biol Chem 2007; 282: 9251-9259.
• 71 Gale AJ, Sun X, Heeb MJ. et al. Nonenzymatic anticoagulant activity of the mutant serine protease Ser360Ala-activated protein C mediated by factor Va. Protein science 1997; 6: 132-140.
• 72 Kerschen EJ, Fernandez JA, Cooley BC. et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant - activated protein C. J Exp Med 2007; 204: 2439-2448.
• 73 Mosnier LO, Gale AJ, Yegneswaran S. et al. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood 2004; 104: 1740-1744.
• 74 Mosnier LO, Yang XV, Griffin JH. Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem 2007; 282: 33022-33033.
• 75 Mosnier LO, Zampolli A, Kerschen EJ. et al. Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood 2009; 113: 5970-5978.
• 76 Sun Y, Tran S, Norstrøm E. et al. Enhanced rate of cleavage at Arg-306 and Arg-506 in coagulation factor Va by gla domain-mutated human-activated protein C. J Biol Chem 2004; 279: 47528-47535.
• 77 Sun YH, Shen L, Dahlbäck B. Gla domain-mutated human protein C exhibiting enhanced anticoagulant activity and increased phospholipid binding. Blood 2003; 101: 2277-2284.
• 78 Zhang L, Castellino F. The binding energy of human coagulation protein C to acidic phospholipid vesicles contains a major contribution from leucine 5 in the y-carboxyglutamic acid domain. J Biol Chem 1994; 269: 3590-3595.
• 79 Preston R, Ajzner E, Razzari C. et al. Multifunctional specificity of the protein C/activated protein C Gla domain. J Biol Chem 2006; 281: 28850-2887.
• 80 Christiansen W, Jalbert L, Robertson R. et al. Hydrophobic amino acid residues of human anticoagulation protein C that contribute to its functional binding to phospholipid Vesicles. Biochemistry 1995; 34: 10376-10382.
• 81 McDonald J, Shah A, Schwalbe R. et al. Comparison of naturally occurring vitamin K-dependent proteins: correlation of amino acid sequences and membrane binding properties suggests a membrane contact site. Biochemistry 1997; 36: 5120-5127.
• 82 Shen L, Shah A, Dahlbäck B. et al. Enhancing the activity of protein C by mutagenesis to improve the membrane-binding site: studies related to Proline-10. Biochemistry 1997; 36: 16025-16031.
• 83 Zhang L, Jhingan A, Castellino F. Role of individual γ-carboxyglutamic acid residues of activated human protein C in defining its in vitro anticoagulant activity. Blood 1992; 80: 942-952.
• 84 Oganesyan V, Oganesyan N, Terzyan S. et al. The crystal structure of the endothelial protein C receptor and a bound phospholipid. J Biol Chem 2002; 277: 24851-24854.
• 85 Qureshi S, Yang L, Manithody C. et al. Functional properties and active-site topographies of factor X Gla- and prothrombin Gla-domain chimeras of activated protein C. Biochim Biophys Acta 2008; 1780: 1080-1086.
• 86 Preston R, Villegas-Mendez A, Sun Y. et al. Selective modulation of protein C affinity for EPCR and phospholipids by Gla domain mutation. FEBS J 2005; 272: 97-108.
• 87 Zhang L, Castellino F. A y-Carboxyglutamic Acid (y) Variant (y6D, y7D) of Human Activated Protein C Displays Greatly Reduced Activity as an Anticoagulant. Biochemistry 1990; 29: 10828-10834.
• 88 Zhang L, Castellino F. Role of the Hexapeptide Disulfide Loop Present in the y-Carboxyglutamic Acid Domain of Human Protein C in Its Activation Properties and in the in Vitro Anticoagulant Activity of Activated Protein C. Biochemistry 1991; 30: 6696-6704.
• 89 Gaussem P, Gandrille S, Duchemin J. et al. Influence of six mutations of the protein C gene on the Gla domain conformation and calcium affinity. Thromb Haemost 1994; 71: 748-754.
• 90 Gandrille S, Alhenc-Gelas M, Gaussem P. et al. Five novel mutations located in exons III and IX of the protein C gene in patients presenting with defective protein C anticoagulant activity. Blood 1993; 82: 159-168.
• 91 Bovill E, Tomczak J, Grant B. et al. Protein CVermont: symptomatic type II protein C deficiency associated with two GLA domain mutations. Blood 1992; 79: 1456-1465.
• 92 Thariath A, Castellino F. Highly conserved residue arginine-15 is required for the Ca2+-dependent properties of the gamma-carboxyglutamic acid domain of human anticoagulation protein C and activated protein C. Biochem J 1997; 322: 309-315.
• 93 Iijima K, Fukuda C, Nakamura K. et al. A new hereditary abnormal protein C (protein C Yonago) with a dysfunctional Gla-domain. Thromb Res 1991; 63: 249-257.
• 94 Mimuro J, Muramatsu S, Kaneko M. et al. An abnormal protein C (protein C Yonago) with an amino acid substitution of Gly for Arg-15 caused by a single base mutation of C to G in codon 57 (CGG-->GGG). Deteriorated calcium-dependent conformation of the gamma-carboxyglutamic acid domain relevant to a thrombotic tendency. Int J Hematol 1993; 57: 9-14.
• 95 Harmon S, Preston RJS, Ainle FN. et al. Dissociation of activated protein C functions by elimination of protein S cofactor enhancement. J Biol Chem 2008; 283: 30531-30539.
• 96 Rezaie A, Esmon C. The function of calcium in protein C activation by thrombin and the thrombin-thrombomodulin complex can be distinguished by mutational analysis of protein C derivatives. J Biol Chem 1992; 267: 26104-26109.
• 97 Ohlin A, Landes G, Bourdon P. et al. Beta-hydroxyaspartic acid in the first epidermal growth factor-like domain of protein C. Its role in Ca2+ binding and biological activity. J Biol Chem 1988; 263: 19240-19248.
• 98 Ohlin A, Björk I, Stenflo J. Proteolytic formation and properties of a fragment of protein C containing the gamma-carboxyglutamic acid rich domain and the EGF-like region. Biochemistry 1990; 29: 644-651.
• 99 Rezaie A, Esmon C. Proline at the P2 position in protein C is important for calcium-mediated regulation of protein C activation and secretion. Blood 1994; 83: 2526-2531.
• 100 Yang L, Prasad S, Di Cera E. et al. The conformation of the activation peptide of protein C is influenced by Ca2+ and Na+ binding. J Biol Chem 2004; 279: 38519-38524.
• 101 Grinnell B, Gerlitz B, Berg D. Identification of a region in protein C involved in thrombomodulin-stimulated activation by thrombin: potential repulsion at anion-binding site I in thrombin. Biochem J 1994; 303: 929-933.
• 102 Friedrich U, Nicolaes G, Villoutreix B. et al. Secondary substrate-binding exosite in the serine protease domain of activated protein C important for cleavage at Arg-506 but not at Arg-306 in factor Va. J Biol Chem 2001; 276: 2305-2308.
• 103 Gale A, Tsavaler A, Griffin J. Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem 2002; 277: 28836-28840.
• 104 Friedrich U, Blom A, Dahlbäck B. et al. Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C. J Biol Chem 2001; 276: 24122-24128.
• 105 Gerlitz B, Grinnell B. Mutation of protease domain residues Lys37-39 in human protein C inhibits activation by the thrombomodulin-thrombin complex without affecting activation by free thrombin. J Biol Chem 1996; 271: 22285-22288.
• 106 Glasscock L, Gerlitz B, Coopera S. et al. Basic residues in the 37-loop of activated protein C modulate inhibition by protein C inhibitor but not by a1-antitrypsin. Biochim Biophys Acta 2003; 1649: 106-117.
• 107 Manithody C, Fay P, Rezaie A. Exosite-dependent regulation of factor VIIIa by activated protein C. Blood 2003; 101: 4802-4807.
• 108 Alhenc-Gelas M, Gandrille S, Aubry M. et al. Thirty-three novel mutations in the protein C gene. French INSERM network on molecular abnormalities responsible for protein C and protein S. Thromb Haemost 2000; 83: 86-92.
• 109 Vincenot A, Gaussem P, Pittet J. et al. Amino acids 225-235** of the protein C serine-protease domain are important for the interaction with the thrombin-thrombomodulin complex. FEBS lett 1995; 367: 153-157.
• 110 Fuentes-Prior P, Iwanaga Y, Huber R. et al. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature 2000; 404: 518-525.
• 111 Fisher C, Greengard J, Griffin J. Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen. Protein Sci 1994; 3: 588-599.
• 112 Shen L, Villoutreix B, Dahlbäck B. Interspecies loop grafting in the protease domain of human protein C yielding enhanced catalytic and anticoagulant activity. Thromb Haemost 1999; 82: 1078-1087.
• 113 Yang L, Manithody C, Rezaie A. The functional significance of the autolysis loop in protein C and activated protein C. Thromb Haemost 2005; 94: 60-68.
• 114 Cramer T, Gale A. Function of the activated protein C (APC) autolysis loop in activated FVIII inactivation. Br J Haematol 2011; 153: 644-654.
• 115 Gale A, Heeb M, Griffin J. The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites. Blood 2000; 96: 585-593.
• 116 Shen L, Dahlbäck B, Villoutreix B. Tracking structural features leading to resistance of activated protein C to α1-antitrypsin. Biochemistry 2000; 39: 2853-2860.
• 117 Shen L, Villoutreix B, Dahlbäck B. Involvement of Lys 62[217] and Lys 63[218] of Human Anticoagulant Protein C in Heparin Stimulation of Inhibition by the Protein C Inhibitor. Thromb Haemost 1999; 82: 72-79.
• 118 Yang L, Bae JS, Manithody C. et al. Identification of a Specific Exosite on Activated Protein C for Interaction with Protease-activated Receptor 1. J Biol Chem 2007; 282: 25493-25500.
• 119 Yegneswaran S, Kojima Y, Nguyen P. et al. Factor Va residues 311-325 represent an activated protein C binding region. J Biol Chem 2007; 282: 28353-28361.
• 120 Yang L, Manithody C, Rezaie A. Activation of protein C by the thrombin-thrombomodulin complex: Cooperative roles of Arg-35 of thrombin and Arg-67 of protein C. PNAS 2006; 103: 879-884.
• 121 Ní Ainle F, O'Donnell J, Johnson J. et al. Activated protein C N-linked glycans modulate cytoprotective signaling function on endothelial cells. J Biol Chem 2011; 286: 1323-1330.
• 122 Rezaie A, Esmon C. Conversion of glutamic acid 192 to glutamine in activated protein C changes the substrate specificity and increases reactivity toward macromolecular inhibitors. J Biol Chem 1993; 268: 19943-19948.
• 123 Soriano-Garcia M, Padmanabhan K, de Vos A. et al. The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistry 1992; 31: 2554-2566.